Continued strong growth

Record result but rising costs

Strix (KETL LN) - Interim results & CMD

Strix has announced interim results for the six months to June showing revenue up 28.6% to £65.2m. The strong top line growth, driven by its 2022 acquisition of Billi, has resulted in gross profits rising 22.6% to £23.9m. Excluding Billi, revenue was down c. 14% yoy. Following updated guidance in today’s announcement, along with its Capital Markets Day, we adjust our forecasts to reflect the slower than anticipated economic recovery along with the impact rising interest rates have had on profita

Mpac Group+ (MPAC, House Stock at 210p) - HY results; recovery continues

Judges Scientific - Interim results – Excellent H1 underpins FY2023 with upside potential to FY2024E

Judges Scientific is a group focused on acquiring and developing companies in the scientific instrument sector. Judges has delivered an excellent first half with order books reaching a new mid-year record of 22.4 weeks. H1 revenue increased by 32% (organic +16.5%) to £61.3m (H1-22: £46.4m) which helped yield an adjusted pre-tax profit of £12.8m (H1-22 £9.6m), a 33% YoY increase (organic: +12%), with EBITA margin climbing to 23.2% (H1-22: 21.8%). Adjusted fully diluted EPS increased 22% to 150.3p

LIBERUM: Judges Scientific: Strong H1, FY23E well underpinned

Hybridan Small Cap Feast - 11 Sep 23

11th September 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment ob

Interims and earnings update

LIBERUM: SThree: Q3 demonstrates further resilience

LIBERUM: Safestyle: Looking to strengthen balance sheet

Wincanton (WIN LN) - Transformational pension agreement

Wincanton has announced a very positive outcome of the 2023 Triennial Valuation, agreed with the Trustees. The Group and the Trustees have decided that no further contributions are now payable into the Pension Scheme because of the 2023 valuation. Previously, contributions for the year ending 31 March 2024 would have been £23.6m, and £25m each year from April 2024 to March 2027, increasing in line with the Retail Prices Index. The free cash and balance sheet position of the Group is transformed,

Water Intelligence - Positive H1 results, adj. PBT up 18%, cash on the balance sheet

WATR has published a strong set of results this morning, featuring a c.9% lift in revenues, growing margins, double digit profit expansion and net cash on the balance sheet. WATR supplies in-demand water leak detection and related services across the whole of the US, and also in international markets including the UK, Australia and Canada. The company's operating model has generated double-digit CAGR consistently over the past decade, and this is another set of results which highlight WATR's ac

Interim results

Water Intelligence has reported interims that were slightly ahead of our expectations and we maintain our FY23 estimates.

Powerhouse Energy - Key Patent Protection Granted

Powerhouse has achieved important protection of the IP around its Distributed Modular Generation technology. This adds to additional protection from the complexity of all ATT processes which already gives the company a high degree of know-how protection. The move helps to consolidate the IP in our view and brings useful validation to the technology.

Artificial intelligence in UK biopharma and healthcare 11/09/2023

Artificial intelligence (AI) continues to accelerate at full speed, first by imitating the workings of a human brain and now it is drawing concepts of evolution, sometimes with synthetic data, artificially manufactured for training purposes or for privacy protection, and sometimes not even with human intervention. In this note, we examine how AI is being developed and applied by the NHS and UK mid/small cap companies for the benefit of human health and wellbeing. AI in drug discovery and devel